Navigation Links
Par Pharmaceutical Reports Third-Quarter 2007 Results
Date:12/20/2007

5 million, representing the premium paid, was charged to R&D in the third quarter.

Third-quarter selling, general and administrative (SG&A) expense decreased 15.3 percent to $33.9 million. The decrease in 2007 SG&A expense was primarily due to the non-recurrence of severance costs incurred in 2006 for executives of $7.1 million, partially offset by increased costs associated with the expansion of finance and accounting functions and increased professional costs related to the Company's restatement of prior periods.

2007 Financial Outlook

Par has adjusted its previously announced guidance for full-year 2007 earnings per diluted share of $1.45-$1.50 from $1.35-$1.50. Total net revenue is expected to be between $760-$780 million. SG&A is expected to be $130-$133 million, including approximately $2 million in severance costs. Research and development cost is projected to be in the range of $75-$80 million, including approximately $19 million in branded milestone payments. Total projected expenses for the full-year include approximately $18-20 million of share-based compensation and $24-$26 million of depreciation and amortization expenses. Adjusting for non-GAAP items highlighted on the summary of estimated operating results for full year 2007 at the end of this press release, full year earnings per diluted share is projected to be $1.50-$1.55.

Stock Repurchase Program

Since October 1, 2007, Par has repurchased 1,643,094 shares of its common stock at a total cost of $31.5 million. On September 28, 2007, Par announced that its Board of Directors had authorized the repurchase of up to $75 million of the Company's common stock.

Conference Call

Par has scheduled a conference call for Thursday, December 20, 2007 at 9:00 am EST to discuss results for the third quarter of 2007. Par invites investors and the general public to listen to a webcast of the conference call. Access to the live webcast can be made via the Company's webs
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... Dallas, Texas (PRWEB) October 20, 2014 ... therapeutic development for Partial Seizure, complete with comparative ... target, mechanism of action (MoA), route of administration ... and featured news and press releases. It also ... for Partial Seizure and special features on late-stage ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that provides ... its latest designs of 2014 mother of the ... outfits are offered with big discounts, up to 70% ... 30 can enjoy this special offer. , Owing ... has become one of the leading brands in the ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Stephen T. Greenberg, ... been nominated for the 10th consecutive year as one of ... Dr. Greenberg was also been nominated as the best provider ... also nominated as best Day Spa and best Laser Treatment ... December 14th and readers can vote for the contest once ...
(Date:10/19/2014)... OCTOBER 20, 2014 – The U.S. Government has ... treat Alzheimer,s disease by 2025. However, a workgroup ... the research milestones in the U.S. Government,s National ... in scope, increased in scale, and adequately funded ... series of proposals by the workgroup to enlarge ...
(Date:10/19/2014)... Dallas, Texas (PRWEB) October 19, 2014 ... in demand for proton therapy despite the high-cost structure ... resulting in market growth. , Analysts forecast the Global ... CAGR of 9.50 percent over the period 2013-2018. According ... this market is the technological advances in medical diagnostics ...
Breaking Medicine News(10 mins):Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Dr. Stephen T. Greenberg – Nominated for the 10th Consecutive Year for One of Long Island’s Best Cosmetic Surgeons for 2015 by the Long Island Press 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 3Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 4Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 5Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 6Health News:Proton Therapy Market to Grow at 9.50% CAGR to 2018 Forecasts a New Research Report at Sandlerresearch.org 2Health News:Proton Therapy Market to Grow at 9.50% CAGR to 2018 Forecasts a New Research Report at Sandlerresearch.org 3Health News:Proton Therapy Market to Grow at 9.50% CAGR to 2018 Forecasts a New Research Report at Sandlerresearch.org 4
... Offers a Simple Guide to Organizing Matters of Life ... are not organized with,medical information and life documents to ... Yorong in Lifetime Medical Organizer: A Simple,Guide to Organizing ... (published by AuthorHouse), the new book she wrote with,Richard ...
... Eight Alternatives to Exercise-Induced Asthma, INDIANAPOLIS, May ... chest pains while engaged in physical,activity, the default ... from,exercise-induced asthma (EIA). However, there are several other,explanations ... left untreated. A featured science session at the ...
... 10-K Extension ... ... KVa/KVb), a fully integrated specialty pharmaceutical company that,develops, manufactures, acquires and ... to complete and file its fiscal 2008 Form,10-K with the Securities ...
... Water Beverage Presents Exercise Hydration Without the ... ... A new study presented at the,American College of Sports Medicine Annual ... beverage,developed by researchers for Scientific Food Solutions, LLC, for active,persons hydrates ...
... Paul Sierzenski, MD, RDMS, of Christiana Care Health System, ... care workers with immediate access to patient medical records ... that using radiofrequency devices that electronically contain a persons ... aid and reduce medical charges, two often incompatible goals. ...
... a new study, knowledge of potentially toxic household substances ... The results show that less than one-third of primary ... correctly estimate the toxicity of household poisons. The study ... Medicines 2008 Annual Meeting. , Led by Rika N. ...
Cached Medicine News:Health News:Lifetime Medical Organizer 2Health News:Pediatric Wheezing: If Not Asthma, Then What is It? 2Health News:Pediatric Wheezing: If Not Asthma, Then What is It? 3Health News:KV Pharmaceutical Company Updates Timing of Fiscal 2008 Securities and Exchange Commission Filings 2Health News:KV Pharmaceutical Company Updates Timing of Fiscal 2008 Securities and Exchange Commission Filings 3Health News:Zero-Calorie Aqua-Lyte(R) Hydrates as Well as Traditional Sports Drinks 2Health News:Zero-Calorie Aqua-Lyte(R) Hydrates as Well as Traditional Sports Drinks 3
(Date:10/17/2014)... 17, 2014   DaVita HealthCare Partners Inc. ... the nation,s largest and most innovative health care ... – the company,s award-winning, leadership development and cultural ... teammates from around the globe were in attendance ... Academy is a two-day one-of-a-kind experience for new ...
(Date:10/16/2014)... Mass. , Oct. 16, 2014 Boston ... CE Mark approval for the ACCOLADE TM pacemaker ... leads, ACCOLADE pacemakers are the first to enable patients ... and 3.0 Tesla systems. In addition, the Boston Scientific ... options, allowing higher energy scan sequences, and featuring a ...
(Date:10/16/2014)... , Oct. 16, 2014 ... of guidance on the application of single-use, ... for pharmaceutical and biopharmaceutical products with the ... Application of Single-Use Systems in ... often described as single-use systems (SUS) or ...
Breaking Medicine Technology:DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 2DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 3Boston Scientific Announces Pacemaker CE Mark With Options For Magnetic Resonance Imaging 2Boston Scientific Announces Pacemaker CE Mark With Options For Magnetic Resonance Imaging 3Boston Scientific Announces Pacemaker CE Mark With Options For Magnetic Resonance Imaging 4Boston Scientific Announces Pacemaker CE Mark With Options For Magnetic Resonance Imaging 5PDA Offers Help in Applying Single-Use Systems to Bio/Pharma Operations 2
... , BEIJING, Oct. 20 /PRNewswire-Asia-FirstCall/ ... "the Company") a leading manufacturer, developer,and distributor of Shengmingsu ... of China (PRC), today announced that the Company consummated,the ... of October,16, 2009. , Yongye ...
... COLORADO SPRINGS, Colo., Oct. 20 Colorado-based Traceability Institute ... designed to initiate consensus to achieve multi-system interoperability with ... US food supply chain. , The Traceability Institute,s ... scheduled to take place January 21 & 22, in ...
Cached Medicine Technology:Yongye International Announces Completion of Restructuring 2Yongye International Announces Completion of Restructuring 3Enhanced Food Safety and Systems Interoperability the Themes of 'Food Traceability Interoperability Summit 2010' 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: